Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry
Tim Spelman, Lars Forsberg, Kyla McKay, Anna Glaser, Jan Hillert
MULTIPLE SCLEROSIS JOURNAL | SAGE PUBLICATIONS LTD | Published : 2021
BACKGROUND: The primary objective of this study was to analyse the association between multiple sclerosis (MS) disease-modifying therapy (DMT) exposure and hospitalisation in patients infected with COVID-19. METHODS: Associations between MS DMT exposure and COVID-19 hospitalisation were analysed using univariable and multi-variable-clustered propensity score weighted logistic regression, where the models were clustered on the individual patients to control for patients contributing multiple COVID-19 episodes. FINDINGS: As of 18 January 2021, a total of 476 reported COVID-19 cases had been recorded in MS patients in the Swedish MS registry. Of these, 292 (61.3%) had confirmed COVID-19. The me..View full abstract
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was supported by the Swedish Research Council and the Swedish Brain Foundation.